{"doi":"10.1093/ajhp/zxaa426","title":"Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States","abstract":"KEY POINTS: In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients. PURPOSE: There are currently no FDA-approved medications for the treatment of coronavirus disease 2019 (COVID-19). At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period. METHODS: We conducted a noninterventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19-targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs). RESULTS: A total of 352 patients treated for COVID-19 at 15 US hospitals From April 18 to May 8, 2020, were included in the study. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies used included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 antagonists (9%). Five patients (7.5%) were receiving combination therapy. The rate of use of COVID-19-directed drug therapy was higher in patients with vs patients without a history of asthma (14.9% vs 7%, P = 0.037) and in patients enrolled in clinical trials (26.9% vs 3.2%, P < 0.001). Among those receiving drug therapy, 8 patients (12%) experienced an ADR, and ADRs were recognized at a higher rate in patients enrolled in clinical trials (62.5% vs 22%; odds ratio, 5.9; P = 0.028). CONCLUSION: While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy, including those enrolled in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 treatments.","journal":"American Journal of Health-System Pharmacy","year":2021,"id":206030,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9644,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":567981,"name":"Atheer Dairem","orcid":null,"position":1,"is_corresponding":false},{"id":567175,"name":"William J Moore","orcid":"0000-0001-5385-354X","position":2,"is_corresponding":false},{"id":567982,"name":"Anooj Shah","orcid":null,"position":3,"is_corresponding":false},{"id":343344,"name":"Michael Postelnick","orcid":null,"position":4,"is_corresponding":false},{"id":567176,"name":"Melissa E. Badowski","orcid":"0000-0001-7564-0131","position":5,"is_corresponding":false},{"id":567177,"name":"Sarah M. Michienzi","orcid":"0009-0004-4910-4422","position":6,"is_corresponding":false},{"id":567983,"name":"Jaime Borkowski","orcid":null,"position":7,"is_corresponding":false},{"id":567178,"name":"Radhika S Polisetty","orcid":"0000-0002-9393-9636","position":8,"is_corresponding":false},{"id":518758,"name":"Karen Fong","orcid":null,"position":9,"is_corresponding":false},{"id":567179,"name":"Emily S Spivak","orcid":"0000-0002-4314-9644","position":10,"is_corresponding":false},{"id":567180,"name":"James Beardsley","orcid":"0000-0003-3900-8758","position":11,"is_corresponding":false},{"id":567984,"name":"Cory M. Hale","orcid":null,"position":12,"is_corresponding":false},{"id":567181,"name":"Andrea Pallotta","orcid":"0000-0002-3960-7155","position":13,"is_corresponding":false},{"id":567182,"name":"Pavithra Srinivas","orcid":"0000-0001-8225-2620","position":14,"is_corresponding":false},{"id":342133,"name":"Lucas Schulz","orcid":"0000-0001-6587-5439","position":15,"is_corresponding":false},{"id":339322,"name":"Nathaniel J. Rhodes","orcid":"0000-0002-0018-5434","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-18T23:51:37.630221Z","pmid":"33537767","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}